Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of ($0.28), $0.10 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $8.96 million versus the consensus estimate of $9.19 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.